|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||8.50 / 24.43|
Jim Cramer focuses on American Airlines, Salesforce.com, Realty Income, Proctor & Gamble, United Bankshares, iRobot, Dominion Energy.
Good earnings reports, cooling oil, and tech leadership all contributed to Thursday's gains, says Jim Cramer. Along with no explosive presidential tweets.
Tesla's Model Y could begin production in November 2019, but don't get your hopes up.
Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.
The embattled activist is reportedly experiencing significant redemptions as investors seek to flee his fund. A campaign at the payroll processor in 2018 is a real possibility as Ackman has $500 million committed to a co-investment targeting the company
Alkermes says the rejection of antidepressant drug ALKS 5461 is a head-scratcher, and it's calling for a prompt meeting with the regulator to get to the bottom of the decision.
Here's what you need to know now for Thursday, March 22.
What do the charts and indicators look like today? Let's check.
There are still skeptics when it comes to Valeant Pharmaceuticals -- and for good reason.
Stocks dropped on Wednesday as global investors parse potentially hawkish comments from Federal Reserve Chairman Jerome Powell and fourth-quarter GDP meets expectations.
Politics, Davos, news -- none of it matters as much as earnings. Here's Jim Cramer's game plan for next week.
With the stock of the drugmaker hovering around $23 a share and its reputation bloodied, CEO Joe Papa tried to explain his company's comeback efforts to investors.
Insurgent managers had another busy year. But behind the numbers there were some fascinating trends and surprising tactics. Here's our review of the year that was.
The drugmaker's stock has rallied about $10 in just a few weeks, so a period of consolidation or sideways movement would be expected.
In markets like this, Jim Cramer says, tune out the noise and look at individual stocks like Disney, Boeing and Caterpillar.
Not all stocks are created equal and it's the CEOs who make the difference.
There are plenty of reasons why the stock market isn't falling, from defense and aerospace, to booming energy, to reduced regulation.
Upcoming catalysts will redefine the biotech market -- and here are 3 names that will feel the impact.
The stock is performing better than it has in a long time.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMZN, CKH, GDDY, PRSC, QGEN, SHLM, VRX Downgrades: BRG, CZWI, FBP, HAIN, LNCE, PIH, TAIT, TPR, TTWO Initiations: ASIX, CWH Read on to get TheStreet Quant Ratings' detailed report:
Valeant has long been a stock that nobody wanted to touch -- but drama-free earnings and a bullish breakout move are actually making this stock look buyable in the final stretch of 2017.
Here's what you need to know now for Tuesday, Nov. 7.
The insurgent hedge fund manager, who suggested he may be back in 2018 with another boardroom battle, fails in his effort to elect three dissident directors to the board of the payroll processor.
U.S. stock futures suggest Wall Street will open mixed on Tuesday, after the benchmark indexes rallied to fresh records during the previous trading session.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.